Relay Therapeutics (RLAY) Stock Price, News & Analysis

Company Overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $4.11 to $4.59
• 50-Day Range: $3.81 to $6.16
• 52-Week Range: $3.50 to $11.16
• Volume: 3.39 million shs
• Average Volume: 1.65 million shs
• Market Capitalization: $746.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.50
• Consensus Rating: Moderate Buy

Relay Therapeutics Stock Analysis - MarketRank™

Relay Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 618th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Relay Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Relay Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Relay Therapeutics are expected to decrease in the coming year, from ($2.55) to ($2.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Relay Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Relay Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Relay Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.93% of the outstanding shares of Relay Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Relay Therapeutics has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Relay Therapeutics has recently increased by 23.76%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Relay Therapeutics does not currently pay a dividend.

Dividend Growth

Relay Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.93% of the outstanding shares of Relay Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Relay Therapeutics has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Relay Therapeutics has recently increased by 23.76%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.17

News Sentiment

Relay Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Relay Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for RLAY on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $781,067.00 in company stock.

Percentage Held by Insiders

Only 4.32% of the stock of Relay Therapeutics is held by insiders.

Percentage Held by Institutions

96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RLAY Stock Analysis - Frequently Asked Questions

How have RLAY shares performed this year?

Relay Therapeutics' stock was trading at $4.12 at the beginning of the year. Since then, RLAY stock has increased by 8.3% and is now trading at $4.46.
View the best growth stocks for 2025 here.

How were Relay Therapeutics' earnings last quarter?

Relay Therapeutics, Inc. (NASDAQ:RLAY) announced its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.77) by $0.14. The firm's revenue was down 100.0% on a year-over-year basis.

When did Relay Therapeutics IPO?

Relay Therapeutics (RLAY) raised $250 million in an initial public offering on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO.

Who are Relay Therapeutics' major shareholders?

Top institutional shareholders of Relay Therapeutics include SG Americas Securities LLC (0.05%). Insiders that own company stock include Mark Murcko, Sanjiv Patel, Donald A Bergstrom, Brian Adams, Peter Rahmer, Thomas Catinazzo and Andy Porter.
View institutional ownership trends.

How do I buy shares of Relay Therapeutics?

Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Relay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Relay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Novo Nordisk A/S (NVO), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 1/20/2025
• Next Earnings (Estimated): 2/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RLAY
• CUSIP: N/A
• CIK: 1812364
• Web: www.relaytx.com
• Phone: 617-370-8837
• Fax: N/A
• Employees: 330
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.50
• High Stock Price Target: $28.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +359.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-341,970,000.00
• Net Margins: N/A
• Pretax Margin: -3,449.57%
• Return on Equity: -45.75%
• Return on Assets: -40.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.42
• Quick Ratio: 18.42

Sales & Book Value

• Annual Sales: $25.55 million
• Price / Sales: 29.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.90 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 167,380,000
• Free Float: 160,152,000
• Market Cap: $746.51 million
• Optionable: Optionable
• Beta: 1.60